Arrowstreet Capital, Limited Partnership Catalyst Pharmaceuticals, Inc. Transaction History
Arrowstreet Capital, Limited Partnership
- $108 Billion
- Q1 2024
A detailed history of Arrowstreet Capital, Limited Partnership transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 12,921 shares of CPRX stock, worth $200,146. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,921Holding current value
$200,146% of portfolio
0.0%Shares
14 transactions
Others Institutions Holding CPRX
# of Institutions
277Shares Held
95.7MCall Options Held
40.6KPut Options Held
67.2K-
Black Rock Inc. New York, NY17.7MShares$275 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$141 Million3.01% of portfolio
-
State Street Corp Boston, MA8.15MShares$126 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.98MShares$124 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.74MShares$42.4 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $1.59B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...